HomeBIIB • NASDAQ
add
Biogen Inc
Previous close
$201.99
Day range
$198.11 - $205.36
Year range
$189.44 - $319.76
Market cap
29.43B USD
Avg Volume
1.30M
P/E ratio
25.39
Dividend yield
-
Primary exchange
NASDAQ
Top news
Q1 earnings report for Biogen
News about Biogen CEO Chris Viehbacher
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 2.39B | -6.20% |
Operating expense | 1.31B | -1.59% |
Net income | 249.70M | -54.63% |
Net profit margin | 10.46 | -51.66% |
Earnings per share | 2.95 | -27.16% |
EBITDA | 601.20M | -21.40% |
Effective tax rate | 14.64% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 1.05B | -78.54% |
Total assets | 26.84B | 9.33% |
Total liabilities | 12.05B | 7.88% |
Total equity | 14.80B | — |
Shares outstanding | 145.36M | — |
Price to book | 1.98 | — |
Return on assets | 4.19% | — |
Return on capital | 5.19% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | 249.70M | -54.63% |
Cash from operations | 12.50M | 107.14% |
Cash from investing | -652.30M | -362.30% |
Cash from financing | -646.10M | -8,631.08% |
Net change in cash | -1.24B | -383.03% |
Free cash flow | -596.10M | -84.17% |
About
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland. Wikipedia
Founded
1978
Headquarters
Website
Employees
7,570